Market factor

Cervical Dystonia Market Factor Analysis 2018 to 2023 | Introduction of new drugs | Treatment options mainly drive market growth – says MRFR

Cervical dystonia is a neurological movement disorder associated with involuntary movement of the neck. It is also known as spasmodic torticollis. According to the study, it was estimated that women are more prone to this disorder – Future analysis 2023

Global Cervical Dystonia Market – Overview

Cervical dystonia is a neurological movement disorder associated with involuntary movement of the neck. It is also known as spasmodic torticollis. According to the study, it was estimated that women are more prone to this disorder.

That being said, there are few obstacles to the growth of this market such as high cost of research and development leading to increase in drug cost, lower awareness of the severity of the disease in developing regions. development and underdeveloped. These factors are hampering the growth of the cervical dystonia market. Experts forecast that the global Cervical Dystonia market is expected to grow at 5% CAGR during the period 2017-2023.

Request a sample report @

Global Cervical Dystonia Market – Market Scenario

Cervical dystonia is a rare disease also known as spastic torticollis. It is one of the chronic painful neurological movement disorders causing involuntary rotation of the neck in any direction. It is a rare disease. The major driving factors behind the Cervical Dystonia Market are the increase in aging population across the world. Women are more likely to be affected by cervical dystonia. On the other hand, the success rate of the treatment and the increase in the cost of the treatment are the major cause for restraining the growth of the Cervical Dystonia market.

Global Cervical Dystonia Market Competitive Analysis

The global market is made up of players such as ALLERGAN (Ireland), Solstice Neurosciences LLC (US), Ipsen Biopharmaceuticals Inc. (France), Merz Inc (US), US WorldMeds, LLC (US) Addex Therapeutics (Switzerland), Revance Therapeutics, Inc. (US), and many more. These are some of the leading competitive players in the global Cervical Dystonia Market and are featured in the MRFR Analysis report.

The global cervical dystonia market is a dynamic market with a number of drugs and therapies available in the market. There are few companies involved in the development of the drugs which are now widely used around the world for the treatment of cervical dystonia. There are great developments taking place in the therapeutic space of cervical dystonia.

Revance Therapeutics Inc. launched in 2016 a Phase II study of RT002 for the treatment of cervical dystonia. The Company recently completed its Phase II program. In November 2017, the company announced the completion of its Phase II program with positive results. The company now plans to implement the Phase 3 program for injectable RT002 to treat cervical dystonia.

ALLERGAN has introduced BOTOX (onabotulinumtoxinA) for the treatment of cervical dystonia. It is prescribed for people 16 years of age and older with cervical dystonia. It is an intramuscular drug.

Solstice Neurosciences LLC introduced MYOBLOC (rimabotulinumtoxinB), which was the first FDA-approved treatment for cervical dystonia. It is used for the treatment of cervical dystonia in adults to reduce the severity of the abnormal head position and neck pain associated with cervical dystonia.

Ipsen Biopharmaceuticals Inc., a French company, has introduced Dysport (abobotulinumtoxinA) for the treatment of adults with cervical dystonia.

Global Cervical Dystonia Market – Regional analysis

The Americas have the largest market for cervical dystonia. The increase in the number of people suffering from cervical dystonia in America has helped to increase the market in this region. Beside this, the increase in the neurotoxins market, the increase in treatments for muscle movement disorders, and the increase in the aging population in this region have fueled the growth of this market in the US region. Due to a huge aging of the population in Canada, the market is growing at a significant rate in this region. According to the study, women are more prone to cervical dystonia than men.

Europe has the second largest market which mainly contributed by UK, Germany and France. A well-developed health sector, improved infrastructure and increased health spending have increased the market in this region.

Asia-Pacific is expected to be the fastest growing region for cervical dystonia market. Asia-Pacific is the developing region and a huge population base in this region is the main driver for the growth of the market. Along with this continuous development of the healthcare industry and increasing aging population in Asia-Pacific, market growth has been fueled. India and China are the major market for cervical dystonia. Due to the lower development of the medical and healthcare sector, the Middle East and Africa region currently contributes the least to the cervical dystonia market.

Get an exclusive discount @

About Us:

Market Research Future (MRFR), enables clients to disentangle the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Report (HCRR), Raw Research Report (3R), Research Continuous (CFR) and Market Research and Advisory Services.

Contact us:

Future market research

Office n ° 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Telephone: +1 646 845 9312

E-mail: [email protected]

Leave a Reply

Your email address will not be published.